Comparative Pharmacology
Head-to-head clinical analysis: DEFERASIROX versus FERRIPROX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERASIROX versus FERRIPROX.
DEFERASIROX vs FERRIPROX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron burden in transfusion-dependent patients.
Deferiprone is an iron chelator that forms a stable complex with ferric iron (Fe3+), promoting its excretion primarily in urine. It reduces iron overload in tissues and prevents organ damage from excess iron.
Initial: 20 mg/kg orally once daily. Maintenance: 20-40 mg/kg orally once daily (maximum 40 mg/kg/day).
25 mg/kg orally three times daily, not to exceed 100 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is 8–16 hours in patients with transfusional iron overload; higher iron burden prolongs half-life due to enterohepatic recirculation.
Clinical Note
moderateDeferasirox + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateDeferasirox + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox."
Clinical Note
moderateCarprofen + Deferasirox
Terminal elimination half-life is approximately 2.5 to 4 hours; clinical context: requires thrice-daily dosing to maintain therapeutic chelation
Primarily fecal (84%) as unchanged drug via biliary excretion; renal excretion accounts for approximately 8% as unchanged drug and metabolites.
Renal: approximately 85% as unchanged drug and metabolites (mainly glucuronide conjugate); fecal: <5%
Category C
Category C
Iron Chelator
Iron Chelator
"The risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox."